Mucinex Dm 12Hr Chest Congestion & Cough Medicine For Adults, Cold And Cough Medicine For Excess Mucus Relief, 600 Mg Guaifenesin & 30 Mg Dextromethorphan Hbr, 68 Bi-Layer Tablets

Cough & Cold Medicine For Adults: Mucinex Dm 12 Hr Expectorant & Cough Suppressant Packs A Powerful Punch With 30 Mg Dextromethorphan Hbr & 600 Mg Guaifenesin Extended Release Tablets Excess Mucus Relief: Powerful Multi-Symptom Relief; Mucinex Dm 12Hr Lasts Up To 12 Hours, Provides Relief For Your Chest Congestion And Makes Coughs More Productive Expectorant For Adults: Mucinex Dm Helps Clear Lungs Of Excess Mucus And Phlegm; Say Goodbye To Chest Congestion And Cough, Say Hello To Excess Mucus Relief With Our Original Bi-Layer Tablets Extended Release Guaifenesin: Experience Long-Lasting Symptom Relief With Mucinex Dm 12Hr Extended-Release 600 Mg Guaifenesin And 30 Mg Dextromethorphan Hbr Tablets Trusted Brand: Mucinex Is The #1 Cough & Cold Brand Doctor'S Trust* And Is Also The #1 Pharmacist Recommended Otc Expectorant**; Get The Brand That Doctors Trust And Recommend Mucinex Dm Extended-Release Bi-Layer Tablets Provide Powerful Symptom Relief. The Product Controls Cough, Relieves Chest Congestion, Thins And Loosens Mucus And Lasts For 12 Hours. It Contains A Unique Bi-Layer Tablet - One Layer For Immediate Release And One Layer For Extended Release, So The Medicine Starts To Release Right Away And Lasts For Up To 12 Hours, So You Can Say Goodbye To Retaking Medicine Every 4 Hours. Mucinex Is The #1 Cough & Cold Brand Doctors Trust* And The #1 Pharmacist Recommended Brandã¢Â† As Well. This Product Contains 20 Tablets. It Can Be Used By Adults And Children 12 Years Of Age And Over. Key Symptoms Relieved: Mucinex Dm Extended-Release Bi-Layer Tablets Control Cough, Relieve Chest Congestion And Thin And Loosen Mucus Active Ingredients: Contains Guaifenesin Which Is An Expectorant That Relieves Chest Congestion And Thins & Loosens Mucus Making Cough More Productive And Dextromethorphan Hbr Which Acts As A Cough Suppressant Use As Directed. *Iqvia Using Provoice Survey, December 2021 †U.S. News & World Report/Pharmacy Times 2022-2023